title: Hematopoietic stem cell transplantation in advanced cutaneous T-cell lymphoma.
abstract: We retrospectively reviewed data pertaining to five patients with cutaneous T-cell lymphoma (CTCL) who had received hematopoietic stem cell transplantation (HSCT) between 2004 and 2015 at Kurume University Hospital, along with their clinical data until March 2016. For patients with advanced CTCL eligible for HSCT, autologous HSCT was performed when they responded well to chemotherapy, and allogeneic HSCT was selected for patients with advanced mycosis fungoides (MF)/Sézary syndrome (SS) and CTCL other than MF/SS with poor chemosensitivity. Two patients (primary cutaneous anaplastic large cell lymphoma and primary cutaneous CD8+aggressive epidermotropic cytotoxic T-cell lymphoma) who responded well to chemotherapy received autologous HSCT: one patient was alive in partial remission and the other died due to therapy-related acute myeloid leukemia without disease relapse. In the remaining three patients with MF or SS, allogeneic HSCT was performed. Although one patient with MF died due to disease progression, the remaining two patients were alive in complete remission. Although there were two deaths in this study, the outcomes were considered satisfactory.
authors.affiliation: Department of Dermatology, Kurume University School of Medicine, Kurume, Japan.
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Saruta
authors.affiliation: Department of Dermatology, Kurume University School of Medicine, Kurume, Japan.
authors.forename: Chika
authors.identifier: http://orcid.org/0000-0001-8341-7300
authors.initials: C
authors.lastname: Ohata
authors.affiliation: Department of Dermatology, Kurume University School of Medicine, Kurume, Japan.
authors.forename: Ikko
authors.initials: I
authors.lastname: Muto
authors.affiliation: Department of Dermatology, Kurume University School of Medicine, Kurume, Japan.
authors.forename: Taichi
authors.initials: T
authors.lastname: Imamura
authors.affiliation: Division of Hematology and Oncology, Department of Medicine, Kitakyushu General Hospital, Kitakyushu, Japan.
authors.forename: Eijiro
authors.initials: E
authors.lastname: Oku
authors.affiliation: Department of Pathology, Kurume University School of Medicine, Kurume, Japan.
authors.forename: Koichi
authors.initials: K
authors.lastname: Ohshima
authors.affiliation: Division of Hematology and Oncology, Department of Medicine, Kurume University School of Medicine, Kurume, Japan.
authors.forename: Koji
authors.initials: K
authors.lastname: Nagafuji
authors.affiliation: Department of Dermatology, Kurume University School of Medicine, Kurume, Japan.
authors.forename: Takekuni
authors.initials: T
authors.lastname: Nakama
mesh_terms: D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D018450:Disease Progression; D005260:Female; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D008297:Male; D008875:Middle Aged; D009182:Mycosis Fungoides / Q000473:pathology / Q000628:therapy*; D012189:Retrospective Studies; D012751:Sezary Syndrome / Q000473:pathology / Q000628:therapy*; D012878:Skin Neoplasms / Q000473:pathology / Q000628:therapy*; D014182:Transplantation, Autologous; D014184:Transplantation, Homologous
keywords: allogeneic; autologous; cutaneous T-cell lymphoma; donor lymphocyte infusions; hematopoietic stem cell transplantation